FDA approves Yescarta to treat relapsed or refractory follicular lymphoma after two lines of systemic therapy – Kite/Gilead Sciences
Kite, a Gilead Company announced that the FDA has granted accelerated approval to Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma… read more.
